Aug 2026· Journal of Medicinal Chemistry· Vol 69 16, pp.
20037-20049
· 0 citations· 58 references
Medicine
TL;DR
CCSite is presented, a protein language model-based framework for discovering covalently ligandable cysteines from protein sequences that uniquely integrates low-rank adaptation of ESM Cambrian with a cysteine-centered encoder-decoder module to capture local microenvironment features and long-range contextual information.
Abstract
Targeted covalent inhibition is an important strategy in modern drug discovery, with cysteine being the most common residue targeted for covalent ligands. Accurate identification of covalently ligandable cysteines is therefore essential, especially for traditionally "undruggable" targets. However, structure-based methods depend on available and reliable protein structures, while sequence-based methods remain scarce and require further improvement. Here, we present CCSite, a protein language model-based framework for discovering covalently ligandable cysteines from protein sequences. It uniquely integrates low-rank adaptation of ESM Cambrian (LoRA-ESMC) with a cysteine-centered encoder-decoder module to capture local microenvironment features and long-range contextual information. Benchmarking and independent evaluation showed that CCSite achieved competitive performance without requiring 3D structures. Moreover, a real-world application revealed that CCSite was capable of prospectively identifying experimentally validated covalent cysteines, and a large-scale screen of human pathogenic X-to-Cys mutations further identified over 2,000 neo-cysteines as covalently ligandable candidates for future covalent drug development.
Design and chemistry principles of cysteine-targeting covalent inhibitors are addressed, with a focus on the diversity of electrophilic warheads currently used or under research, and established motifs are discussed alongside newfound warheads.
Mariana Castelôa, F. Borges, S. Benfeito et al.· European journal of medicina...· 0 citations
CysLENS (Cysteine Ligandability Evaluation through Neighborhood and Chemical Similarity), an integrative framework that prioritizes ligandable interactions by translating chemoproteomic screening data into interpretable cysteine–chemotype signatures, is presented.
Sameek Singh, Maja E. Wierzbińska, Konika Konika et al.· bioRxiv· 0 citations
Irreversible covalent inhibitors have garnered significant attention in recent years. Despite encouraging progress, the vast majority contain electrophiles that target the least abundant amino acid cysteine, substantially limiting target inhibitor design for therapeutic intervention. Here, we generalize 2-ethynylbenzal...
Paul M. Levine, Patrick W. Erickson, Timothy W. Craven et al.· ACS Chemical Biology· 0 citations
Targeted covalent inhibitors can provide potent and durable target modulation, but their development has largely centered on cysteine. Lysine offers a complementary covalent handle because it is widely distributed across catalytic sites, ligand-binding pockets, allosteric regions, and protein-protein interaction interf...
Ming-Jin Luo, Lu-Yu Ma, Guo-Shun Luo et al.· Biochemical Pharmacology· 0 citations
Lysine-directed covalent liganding offers a promising strategy to expand the covalently ligandable proteome beyond cysteine. However, broadly applicable and selective lysine-reactive scaffolds remain limited. Here, we designed SCL-alkyne, a simplified azaphilone probe derived from the natural product sclerotiorin (SCL)...
Wei Ding, Sophie Brameyer, S. Kirsch et al.· bioRxiv· 0 citations
Reversible covalent targeting of cysteine residues offers a powerful strategy for generating potent and tunable ligands, but designing electrophiles with balanced reactivity, stability, and reversible binding remains challenging. Here, we systematically optimized reversible α,β-unsaturated nitrile electrophiles and i...
Yu-Qian Zhang, Meng-Zhu Qi, Xian-Kai Liu et al.· Journal of the American Chem...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.